Hee Yeon Lee, Hoon-Kyo Kim, Kyung Hee Lee, Bong-Seog Kim, Hong Suk Song, Sung Hyun Yang, Joon Hee Kim, Yeul Hong Kim, Jong Gwang Kim, Sang-We Kim, Dong-Wan Kim, Si-Young Kim, Hee Sook Park
Cancer Res Treat. 2014;46(1):19-26. Published online January 15, 2014
PURPOSE This study was conducted to evaluate the efficacy and safety of azasetron compared to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting. MATERIALS AND METHODS This study was a multi-center, prospective, randomized, double-dummy, double-blind and parallel-group trial involving 12 institutions in Korea between May 2005 and December 2005. A total of 265 patients with moderately and highly emetogenic chemotherapy were included and randomly assigned to either the azasetron or ondansetron group. All patients received azasetron (10 mg intravenously) and dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with placebo of ondansetron (orally every 12 hours), and the ondansetron group received ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 2-6. RESULTS Over days 2-6, the effective ratio of complete response in the azasetron and ondansetron groups was 45% and 54.5%, respectively (95% confidence interval, -21.4 to 2.5%). Thus, the non-inferiority of azasetron compared with ondansetron in delayed chemotherapy-induced nausea and vomiting was not proven in the present study. All treatments were well tolerated and no unexpected drug-related adverse events were reported. The most common adverse events related to the treatment were constipation and hiccups, and there were no differences in the overall incidence of adverse events. CONCLUSION In the present study, azasetron showed inferiority in the control of delayed chemotherapy-induced nausea and vomiting compared with ondansetron whereas safety profiles were similar between the two groups.
Citations
Citations to this article as recorded by
Influence of ABCB1 genetic polymorphisms on the antiemetic response to ondansetron-based medication for cisplatin-based chemotherapy in South Indian cancer patients in a tertiary care hospital Ayyar Porkodi, Deepak Gopal Shewade, Goud Alladi Charanraj Current Issues in Pharmacy and Medical Sciences.2023; 36(3): 129. CrossRef
Hiccups in Cancer Patients Receiving Chemotherapy: A Cross-Sectional Study Mevlüde Ergen, Fatma Arikan, Rüya Fırat Çetin Journal of Pain and Symptom Management.2021; 62(3): e85. CrossRef
A Fast and Validated HPLC Method for the Simultaneous Analysis of Five 5-HT3 Receptor Antagonists via the Quantitative Analysis of Multicomponents by a Single Marker Fuchao Chen, Baoxia Fang, Peng Li, Sicen Wang, Amr M. Mahmoud International Journal of Analytical Chemistry.2021; 2021: 1. CrossRef
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Effectiveness of Steroid Rotation in a Japanese Patient with Hiccups Caused by Dexamethasone: a Case Report Hiroki Hosokawa, Hideaki Shimoda, Takayuki Ishii YAKUGAKU ZASSHI.2019; 139(4): 647. CrossRef
Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration Bao-Xia Fang, Fu-Chao Chen, Dan Zhu, Jun Guo, Lin-Hai Wang Oncotarget.2017; 8(63): 106249. CrossRef
Gender Differences in Hiccup Patients: Analysis of Published Case Reports and Case-Control Studies Gyeong-Won Lee, Rock Bum Kim, Se Il Go, Hyun Seop Cho, Seung Jun Lee, David Hui, Eduardo Bruera, Jung Hun Kang Journal of Pain and Symptom Management.2016; 51(2): 278. CrossRef
Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting Bishal Gyawali, Bishesh Sharma Poudyal, Mahesh Iddawela Journal of Global Oncology.2016; 2(3): 145. CrossRef
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review K. Jordan, F. Jahn, M. Aapro Annals of Oncology.2015; 26(6): 1081. CrossRef